Target and Technology
Brentuximab vedotin (ADCETRIS) is an antibody-drug conjugate (ADC) that targets CD30 which is found on the surface of most classical Hodgkin lymphoma (HL) cells and in several types of non-Hodgkin lymphoma, but not commonly found on healthy cells. Brentuximab vedotin uses our proprietary ADC technology and is composed of an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a cytotoxic (cell-killing) agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE when internalized into CD30-expressing cells, resulting in target cell death.
We are developing brentuximab vedotin in collaboration with Takeda Pharmaceutical Company. Under the collaboration, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has commercialization rights in the rest of the world. The companies are funding joint worldwide development costs on a 50:50 basis, except in Japan where Takeda is fully responsible for development costs.
We are conducting a comprehensive clinical development program in more than 70 corporate and investigator clinical trials, including three phase 3 studies designed to evaluate the potential of brentuximab vedotin in earlier lines of its approved indications as well as in many additional types of CD30-expressing lymphomas, including cutaneous T-cell lymphoma (CTCL), mature T-cell lymphomas, commonly referred to as peripheral T-cell lymphoma (PTCL), and B-cell lymphomas. Safety and efficacy of brentuximab vedotin in these investigational programs have not been established.
These phase 3 clinical trials are ongoing:
- Phase 3 ALCANZA trial for CD30-expressing cutaneous T-cell lymphoma (supplemental BLA submitted June 2017)
- Phase 3 ECHELON-1 frontline Hodgkin lymphoma in combination with chemotherapy (top-line data reported)
- Phase 3 ECHELON-2 frontline CD30-expressing mature T-cell lymphomas in combination with chemotherapy (enrollment complete)